CNS Neuroscience & Therapeutics

Cover image for Vol. 22 Issue 6

Edited By: Ding-Feng Su

Impact Factor: 3.931

ISI Journal Citation Reports © Ranking: 2014: 43/255 (Pharmacology & Pharmacy); 68/252 (Neurosciences)

Online ISSN: 1755-5949

Author Guidelines

Authors submitting to CNS Neuroscience & Therapeutics benefit from:

Publishing in a journal with a high Impact Factor
2015 JCR Journal Impact Factor: 3.931

Rapid peer review
Average days from submissions to first decision: 19 days.
Average days from acceptance to online publication ahead of issue publication (Early View): 45 days
Average days from acceptance to final issue publication: 70 days

The option to submit Clinical Trial papers for Expedited Review
First review returned 7 working days from online submission. Proofs ready 7 working days from 'accept' decision. Online PUblication 7 working days from proof approval. Print publication as a 'Late Breaker' paper in the next print issue.

Thank you for your interest in CNS Neuroscience & Therapeutics. Please read the complete Author Guidelines carefully prior to submission, including the section on copyright and page charges. To ensure fast peer review and publication, manuscripts that do not adhere to the following instructions will be returned to the corresponding author for technical revision before undergoing peer review.

Note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium. Once you have prepared your submission in accordance with the Guidelines, manuscripts should be submitted online at

We are looking forward to your submission.


CNS Neuroscience & Therapeutics provides a medium for rapid publication of original clinical, experimental, and translational research papers, timely reviews and reports of novel findings of therapeutic relevance to the central nervous system, as well as papers related to clinical pharmacology, drug development and novel methodologies for drug evaluation. The journal focuses on neurological and psychiatric diseases such as stroke, Parkinson’s disease, Alzheimer’s disease, depression, schizophrenia, and drug abuse.

Review Process
After an initial check, manuscripts are assigned sequentially to Associate Editor by the Editor-in-Chief. The Associate Editor solicits reviewers (typically, two external reviews are sought). The reviewers’ evaluations and Associate Editor comments are compiled by the Editor-in-Chief for disposition and transmittal to the authors. A decision is made usually within four weeks of the receipt of the manuscript.

The Editor-in-Chief will advise authors whether a manuscript is accepted, should be revised or is rejected. Minor revisions are expected to be returned within six weeks of decision; major revisions within six months. Manuscripts not revised within these time periods are subject to withdrawal from consideration for publication unless the authors can provide extenuating circumstances.

A number of manuscripts will have to be rejected on the grounds of priority and available space. A manuscript may be returned to the authors without outside review if the Editor-in-Chief and Associate Editor find it inappropriate for publication in the Journal. Similarly, the Editors may expedite the review process for manuscripts felt to be of high priority in order to reach a rapid decision. Such ‘fast-track decisions’ will normally occur within one week of receipt of the manuscript.

Authors may provide the Editor-in-Chief with the names, addresses and email addresses of up to three suitably qualified individuals of international standing who would be competent to referee the work, although the Editor-in-Chief will not be bound by any such nomination. Likewise, authors may advise of any individual who for any reason, such as potential conflict of interest, might be inappropriate to act as a referee, again without binding the Editor-in-Chief.

The Editor-in-Chief’s decision is final. If, however, authors dispute a decision and can document good reasons why a manuscript should be reconsidered, a rebuttal process exists. In the first place, authors should write to the Editor-in-Chief.

Submission of revised manuscripts
Revised manuscript submissions should include a point by point letter specifying how the author has responded to the reviewers' and editors' comments. Please also highlight the changes to your manuscript within the document by using the track changes mode in Word or by using bold or colored text.

Expedited Review
EXPEDITED is the priority publication service from CNS Neuroscience & Therapeutics exclusively for well conducted, well reported clinical trials. The time-line for Expedited Review papers are as follows. Priority peer review: 7 working days from online submission. Priority proofs: 7 working days from 'accept' decision. Priority online: 7 working days from proof approval to Early View publication. Priority print: 'Late Breaker' publication in the next print issue. Expedited Review is exclusively available for clinical trials (interventional and observational studies). Contact us for more information.

How to apply for Expedited Review
Step #1 - Apply to the Editorial Office at least 1 week before online submission with a detailed abstract, list of authors, contributorship statement, clinical trial registration details, clinical trial data posting details (if available), complete CONSORT or STROBE checklist (note: at this stage replace page numbers on this checklist with the word 'Yes' to confirm that each CONSORT/STROBE recommendation has been followed), details of research funding and disclosures of potential conflicts of interest.

Step #2 - We will confirm that we have received your application and whether we will expedite your peer review. If we accept your application for the Expedited service, you will receive an invoice for $1,500 (non-refundable).

Step #3 - Submit online as an 'EXPEDITED Clinical Trial'. Contact us for more information.

Expedited Conditions
The standard CNS Neuroscience & Therapeutics peer review processes inform all editorial decisions. The details contained in editorial recommendations and decisions about individual submitted papers are not linked to payment - the Expedited service only aims to deliver these recommendations faster. Clinical trials submitted for consideration via the Expedited service may be rejected. The Expedited service charge is not refundable. Contact us for more information.

The journal is committed to integrity in scientific research and recognizes the importance of maintaining the highest ethical standards.

Principles for Publication of Research Involving Human Subjects
Manuscripts must contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in an appropriate version of the Declaration of Helsinki (as revised in Brazil 2013), available at It should also state clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under the study should be omitted. All investigations on human subjects must include a statement that the subject gave informed consent. Patient anonymity should be preserved. Photographs need to be cropped sufficiently to prevent human subjects being recognized (or an eye bar should be used).

In general, submission of a case report should be accompanied by the written consent of the subject (or parent/guardian) before publication; this is particularly important where photographs are to be used or in cases where the unique nature of the incident reported makes it possible for the patient to be identified. While the Editorial Board recognizes that it might not always be possible or appropriate to seek such consent, the onus will be on the authors to demonstrate that this exception applies in their case.

Use of Animals in Research
Any experiments involving animals must be demonstrated to be ethically acceptable and where relevant conform to national guidelines for animal usage in research.

Clinical Trials Registry
We require, as a condition of consideration for publication, registration in a public trials registry. Trials must register at or before the onset of patient enrollment. This policy applies to any clinical trial starting enrollment after 1 January 2006. For trials that began enrollment before this date, we require registration by 1 April 2006, before considering the trial for publication. We define a clinical trial as any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes, such as to study pharmacokinetics or major toxicity (e.g., phase 1 trials), are exempt.

We do not advocate one particular registry, but registration must be with a registry that meets the following minimum criteria: (1) accessible to the public at no charge; (2) searchable by standard, electronic (Internet-based) methods; (3) open to all prospective registrants free of charge or at minimal cost; (4) validates registered information; (5) identifies trials with a unique number; and (6) includes information on the investigator(s), research question or hypothesis, methodology, intervention and comparisons, eligibility criteria, primary and secondary outcomes measured, date of registration, anticipated or actual start date, anticipated or actual date of last follow-up, target number of subjects, status (anticipated, ongoing or closed) and funding source(s).

Registries that currently meet these criteria include: (1) the registry sponsored by the United States National Library of Medicine; (2) the International Standard Randomized Controlled Trial Number Registry; (3) the Australian Clinical Trials Registry; (4) the Chinese Clinical Trials Register; and (5) the Clinical Trials Registry - India.

Reporting Standards
Reporting of randomized controlled trials should follow the guidelines of The CONSORT Statement. Reporting of diagnostic accuracy studies should follow STARD guidelines; Reporting of meta-analyses should follow QUOROM guidelines; Reporting of epidemiological studies should follow STROBE guidelines.

All manuscripts must include a disclosure statement in the body of the manuscript. The statement must declare any financial support or relationships that may pose conflict of interest. This includes any financial arrangements authors have with a company whose product figures prominently in the submitted manuscript or with a company making a competing product. The absence of any interest to disclose must also be stated. The statement should be provided under the heading ‘Disclosure,’ and should appear after the ‘Acknowledgement’ section and before the ‘References’ section.

Authorship and Acknowledgements
The journal adheres to the definition of authorship set up by The International Committee of Medical Journal Editors (ICMJE). The ICMJE recommends that authorship be based on the following 4 criteria: i) Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; ii) Drafting the work or revising it critically for important intellectual content; iii) Final approval of the version to be published; and i) Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Contributors who do not qualify as authors should be mentioned under ‘Acknowledgements’.

Note that CNS Neuroscience & Therapeutics allows at most two authors to be listed as first authors or corresponding authors.

Reproduction of Copyright Material
If excerpts from copyrighted works owned by third parties are included, credit must be shown in the contribution. It is the author’s responsibility to also obtain written permission for reproduction from the copyright owners. For more information visit Wiley’s Copyright Terms & Conditions FAQ at

Plagiarism Detection
The journal employs a plagiarism detection system. By submitting your manuscript to this journal you accept that your manuscript may be screened for plagiarism against previously published works.

Committee on Publication Ethics
The journal is a member of, and subscribes to the principles of the Committee on Publication Ethics (COPE).


(1) Original Articles Word limit: 4000 words maximum including abstract but excluding references, tables and figures. Abstract: 200 words maximum, with sub-headers of Aims, Methods, Results, Conclusion. References: up to 60. Figures/ tables: up to 6. Description: Full-length reports of current research in either basic or clinical science.

(2) Reviews Word limit: 4000 words maximum including abstract but excluding references, tables and figures. Abstract: 200 words maximum. References: up to 150. Figures/tables: minimum 1, maximum 3. Description: Reviews are comprehensive analyses of specific topics. They are submitted upon invitation by the Editors. Proposals for reviews may be submitted; however, in this case authors should only send an outline of the proposed paper for initial consideration. Both solicited and unsolicited review articles will undergo peer-review prior to acceptance.

(3) Clinical Guidelines Word limit: 5000 words maximum including abstract but excluding references, tables and figures. Abstract: 250 words maximum. References: no maximum. Description: Guidelines need to be the product of a large group of individuals who are recognized authorities in their field. Guidelines will be written by a working party to include a steering committee (usually at least 4 members) and other authors representing a wide range of those with special relevant expertise as well as those whose everyday practice will be influenced by the guidelines.

(4) Letters to the Editor Word limit: 1000 words maximum. Abstract: not required. References: 10 maximum. Figures/ tables: 2 maximum. Description: Letters must offer perspective to content published in CNS Neuroscience & Therapeutics or information critical to a certain area. A Letter must reference the original source, and a Response to a Letter must reference the Letter in the first few paragraphs. Letters can use an arbitrary title, but a Response must cite the title of the Letter: e.g. Response to [Title of Letter]. This ensures that readers can track the line of discussion. Letters to the Editor are subjected to peer-review. Submissions may be edited for length, grammatical correctness, and journal style. Authors will be asked to approve editorial changes that alter the substance or tone of a letter or response. In addition, we encourage authors to submit their short communication including new clinical and experimental findings, and new method or technology, under this type of manuscript

(6) Editorial Commentaries Word limit: 1000 words maximum. Title: 20 words maximum. Abstract: not required. References: 10 maximum, including the article discussed. Figures/tables: 2 maximum. Description: Commentaries, upon Editor’s invitation, discuss a paper published in a specific issue and should set the problems addressed by the paper in the wider context of the field. Proposals for Commentaries may be submitted; however, in this case authors should only send an outline of the proposed paper for initial consideration.

(7) Meeting Reports Word limit: 3000 words maximum including abstract but excluding references, tables and figures. Abstract: 250 words maximum, with sub-headers. References: no limit. Figures/ tables: no limit, but 8 figures should be sufficient. Description: Brief reports of symposia and conferences in neuroscience. Reports must be submitted within 2 months of the meeting date in order to maintain their timeliness. Only those Meeting Reports dealing with topics of interest to the readership and that contain novel information and insights from the meeting are accepted for publication. A Meeting Report should be a thoughtful, critical commentary which shows an appreciation of the connections among the various presentations and reveals the consensus, if any, which emerged at the meeting. Before submitting a full Meeting Report, authors should only send an outline of the proposed paper for initial consideration.

(8) Meta-Analyses Word limit: 4000 words maximum including abstract but excluding references, tables and figures. Abstract: 200 words maximum. References: no maximum. Description: Meta-analysis is the use of statistical techniques to integrate and summarize the results of included studies. Authors of reports of meta-analyses of randomized trials are encouraged to submit the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram and checklist. Authors of meta-analyses of observational studies are encouraged to submit the MOOSE (Meta-analysis of Observational Studies in Epidemiology) checklist.


Pre-acceptance English-language editing
Authors for whom English is a second language may choose to have their manuscript professionally edited before submission to improve the English. Visit our site to learn about the options. All services are paid for and arranged by the author.  Please note using the Wiley English Language Editing Service does not guarantee that your paper will be accepted by this journal.

Optimizing Your Article for Search Engines
Many students and researchers looking for information online will use search engines such as Google, Yahoo or similar. By optimizing your article for search engines, you will increase the chance of someone finding it. This in turn will make it more likely to be viewed and/or cited in another work. We have compiled these guidelines to enable you to maximize the web-friendliness of the most public part of your article.

Manuscripts must follow the style of the Vancouver agreement detailed in the International Committee of Medical Journal Editors’ revised ‘Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication’, as presented at:

  • Author name - Please read the section on Authorship carefully for Guidelines on the requirements for authorship listing. Each author’s given name should be followed by family name. Capitalise the first letter of those words/syllables that they hope to be abbreviated in their given name, otherwise, DO NOT capitalize the first letter and use a hyphen to connect it with its anterior word.
  • Spelling - The Journal uses US spelling and authors should therefore follow the latest edition of the Merriam–Webster’s Collegiate Dictionary.
  • Units - All measurements must be given in SI or SI-derived units. For more information about SI units, please go to the Bureau International des Poids et Mesures (BIPM) website.
  • Abbreviations - Must be used sparingly – only where they ease the reader’s task by reducing repetition of long, technical terms. Initially use the word in full, followed by the abbreviation in parentheses. Thereafter use the abbreviation only.
  • Trade names - Drugs should be referred to by their generic names. If proprietary drugs have been used in the study, refer to these by their generic name, mentioning the proprietary name, and the name and location of the manufacturer, in parentheses.

Parts of the manuscript
The length of manuscripts must adhere to the specifications under the section Manuscript Categories. Manuscripts should be presented in the following order: (i) title page, (ii) abstract and key words, (iii) text, (iv) acknowledgments, (v) disclosure, (vi) references, (vii) tables (each table complete with title and footnotes), and (viii) figure legends. Figures and Supplementary Information should be supplied as separate files. Footnotes to the text are not allowed and any such material should be incorporated into the text as parenthetical matter.

Title Page
The title page should contain the following:

(i) The full title of the paper. The title should be short, informative and contain the major key words so that readers and in particular online users will discover the article easily in online search. Titles that are too short may, however, lack important information, such as study design (which is particularly important in identifying randomized controlled trials). Do not use abbreviations in the title.
(ii) A short running title (less than 40 characters).
(ii) The full names of the authors
(iii) The full institutional affiliations at which their work was carried out for each author. The present address of any author, if different from that where the work was carried out, supplied as a footnote.
(iv) The full postal and email address, plus facsimile and telephone numbers, of the author to whom correspondence about the manuscript should be sent
(iv) In keeping with the latest guidelines of the International Committee of Medical Journal Editors, each author's contribution to the paper is to be quantified. For more detail view the ICMJE criteria here.

The length of abstracts must adhere to the word count specifications under the section Manuscript Categories. The abstract should state the main problem, methods, results, and conclusions. It must be factual and comprehensive. The use of abbreviations and acronyms should be limited and general statements (e.g. ‘‘the significance of the results is discussed’’) should be avoided.

Three to five key words should be supplied below the abstract, in alphabetical order, and should be taken from those recommended by the US National Library of Medicine’s Medical Subject Headings (MeSH) browser list.

Authors must use the following subheadings to divide the sections of their Original Article manuscript: Introduction, Methods, Results, Conclusion, Acknowledgment, Disclosure, References, and when relevant, Supplementary Material.

This should include sources of support, including government and industry support. All authors who have contributed to the manuscript must be acknowledged. Medical writers, proofreaders and editors should not be listed as authors, but acknowledged at the beginning or end of the text.

The disclosure statement must declare any financial support or relationships that may pose conflict of interest. The absence of any interest to disclose must also be stated.

The Vancouver system of referencing should be used (examples are given below). In the text, references should be cited using Arabic numerals in the order in which they appear. If cited in tables or figure legends, number according to the first identification of the table or figure in the text. In the reference list, cite the names of all authors when there are six or fewer; when seven or more, list the first three followed by et al. Do not use ibid. or op cit. Reference to unpublished data and personal communications should not appear in the list but should be cited in the text only (e.g. Smith A, 2000, unpublished data). All citations mentioned in the text, tables or figures must be listed in the reference list. Names of journals should be abbreviated in the style used in PubMed. Authors are responsible for the accuracy of the references.

  • Journal article 1. Gibas Z, Prout DF Jr, Pontes JR. Chromosome changes in germ cell tumours of the testis. Cancer Genet Cytogenet 1986; 19: 254-52.
  • Online article not yet published in an issue An online article that has not yet been published in an issue (therefore has no volume, issue or page numbers) can be cited by its Digital Object Identifier (DOI). The DOI will remain valid and allow an article to be tracked even after its allocation to an issue. 1. Furuya R, Takahashi R, Furuya S, et al. Is urethritis accompanied by seminal vesiculitis? Int. J. Urol. DOI: 10.1111/j.1442-2042.2009.02314.x
  • Book 2. Ernstoff M. Urologic Cancer. Blackwell Science, Boston, 1997.
  • Chapter in a book 3. Gilchrist RK. Further commentary: Continent stroma. In: King LR, Stone AR, Webster GD (eds). Bladder Reconstruction and Continent Urinary Diversion. Year Book Medical, Chicago, 1987; 204-5.

Tables should be self-contained and complement, but not duplicate, information contained in the text. Number tables consecutively in the text in Arabic numerals. Type tables on a separate page with the legend above. Legends should be concise but comprehensive – the table, legend and footnotes must be understandable without reference to the text. Vertical lines should not be used to separate columns. Column headings should be brief, with units of measurement in parentheses; all abbreviations must be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be used (in that order) and *, **, *** should be reserved for P-values. Statistical measures such as SD or SEM should be identified in the headings.

Figure legends
Type figure legends on a separate page. Legends should be concise but comprehensive – the figure and its legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement.

All illustrations (line drawings and photographs) are classified as figures. Figures should be numbered using Arabic numerals, and cited in consecutive order in the text. Each figure should be supplied as a separate file, with the figure number incorporated in the file name.

Preparation of Electronic Figures for Publication: Although low quality images are adequate for review purposes, print publication requires high quality images to prevent the final product being blurred or fuzzy. Submit EPS (line art) or TIFF (halftone/photographs) files only. MS PowerPoint and Word Graphics are unsuitable for printed pictures. Do not use pixel-oriented programmes. Scans (TIFF only) should have a resolution of 300 dpi (halftone) or 600 to 1200 dpi (line drawings) in relation to the reproduction size (see below). EPS files should be saved with fonts embedded (and with a TIFF preview if possible). For scanned images, the scanning resolution (at final image size) should be as follows to ensure good reproduction: line art: >600 dpi; half-tones (including gel photographs): >300 dpi; figures containing both halftone and line images: >600 dpi.

  • Size - Figures should be sized to fit within the column (82 mm), intermediate (118 mm) or the full text width (173 mm).
  • Resolution - Figures must be supplied as high resolution saved as .eps or .tif. Halftone figures 300 dpi (dots per inch), Color figures 300 dpi saved as CMYK, figures containing text 400 dpi, Line figures 1000 dpi.
  • Colour figures - Files should be set up as CMYK (cyan, magenta, yellow, black) and not as RGB (red, green, blue) so that colors as they appear on screen will be a closer representation of how they will print in the journal.
  • Text sizing in figures - Lettering must be included and should be sized to be no larger than the journal text or 8 point (Should be readable after reduction – avoid large type or thick lines). Line width between 0.5 and 1 point.

More advice on figures can be found at Wiley’s guidelines for preparation of figures:

Color publication: the journal offers authors publication of color figures free of charge in both the print and online versions of the journal.

Supporting Information
Supporting information is not essential to the article but provides greater depth and background and may include tables, figures, videos, datasets, etc. This material can be submitted with your manuscript, and will appear online, without editing or typesetting. Guidelines on how to prepare this material and which formats and files sizes are acceptable can be found at Wiley Author Services. Please note that the provision of supporting information is not encouraged as a general rule. It will be assessed critically by reviewers and editors and will only be accepted if it is essential.


A cover letter should be included in the ‘Cover Letter Field’ of the ScholarOne system. The text can be entered directly into the field or uploaded as a file. The covering letter must contain i) an acknowledgment that all authors have contributed significantly, and ii) a statement that all authors are in agreement with the content of the manuscript and agree to submission to CNS Neuroscience & Therapeutics.

Two Word-files need to be included upon submission: A title page file and a main text file that includes all parts of the text in the sequence indicated in the section 'Parts of the manuscript', including tables and figure legends but excluding figures which should be supplied separately.

The main text file should be prepared using Microsoft Word, double-spaced. All pages should be numbered consecutively in the top right-hand corner, beginning with the first page of the main text file.

Each figure should be supplied as a separate file, with the figure number incorporated in the file name. For submission, low-resolution figures saved as .jpg or .bmp files should be uploaded, for ease of transmission during the review process. Upon acceptance of the article, high-resolution figures (at least 300 d.p.i.) saved as .eps or .tif files will be required.

Any supplementary material must be uploaded as separate files and designated as "Supplementary Material for Review"

Associate your ScholarOne account with your ORCID iD
ORCID iD is a unique and persistent identifier that distinguishes you from every other researcher and connects you and your research activities. We encourage you to register for an ORCID iD and then associate it with your ScholarOne account. Click here to find out how.


Disclosure Form
After acceptance the Corresponding Author will be provided with a 'Financial Dislosure Form' which must be completed and returned as directed.

Transition to Wiley Production
Accepted papers will be passed to Wiley’s production team for publication. The author identified as the formal corresponding author for the paper will receive an email prompting them to login into Wiley’s Author Services, where via the Wiley Author Licensing Service (WALS) they will be asked to complete an electronic license agreement on behalf of all authors on the paper. More details on the copyright and licensing options for the journal appear below.

Wiley’s Author Services: Tracking your paper’s progress
Author Services also enables authors to track their article through the production process to publication online and in print. Authors can check the status of their articles online and choose to receive automated emails at key stages of production. The corresponding author will receive a unique link that enables them to register and have their article automatically added to the system. Visit for more details on online production tracking and for a wealth of resources including FAQs and tips on article preparation, submission and more.

Once the paper has been typeset the corresponding author will receive an email alert containing instructions on how to provide proof corrections to the article. It is therefore essential that a working email address is provided for the corresponding author.

Page charges
Authors of accepted Original Articles or Meta-analyses will be charged flat page charge publication fee of USD 1,000 per article.

The publication fee will be waived if authors choose to publish their articles as Online Open (Open Access), with which a separate fee (USD 3,000) will be charged.

Early View
The journal offers rapid speed to publication via Wiley’s Early View service. Early View articles are complete full-text articles published online in advance of their publication in a printed issue. Early View articles are complete and final. They have been fully reviewed, revised and edited for publication, and the authors' final corrections have been incorporated. Because they are in final form, no changes can be made after online publication. Early View articles are given a Digital Object Identifier (DOI), which allows the article to be cited and tracked before allocation to an issue. After print publication, the DOI remains valid and can continue to be used to cite and access the article. More information about DOIs can be found at

A PDF reprint of the article will be supplied free of charge to the corresponding author. Additional printed offprints may be ordered online for a fee. Please click on the following link and fill in the necessary details and ensure that you type information in all of the required fields: If you have queries about offprints please e-mail:

Author Marketing Toolkit
The Wiley Author Marketing Toolkit provide authors with support on how to use social media, publicity, conferences, multimedia, email and the web to promote their article.

Accepted papers will be passed to Wiley’s production team for publication. The author identified as the formal corresponding author for the paper will receive an email prompting them to login into Wiley’s Author Services, where via the Wiley Author Licensing Service (WALS) they will be asked to complete an electronic license agreement on behalf of all authors on the paper.

Authors may choose to publish under the terms of the journal’s standard copyright transfer agreement (CTA), or under open access terms made available via Wiley OnlineOpen.

Standard Copyright Transfer Agreement: FAQs about the terms and conditions of the standard CTA in place for the journal, including standard terms regarding archiving of the accepted version of the paper, are available at Copyright Terms and Conditions FAQs.

Note that in signing the journal’s license agreement authors agree that consent to reproduce figures from another source has been obtained.

OnlineOpen – Wiley’s Open Access Option: OnlineOpen is available to authors of articles who wish to make their article freely available to all on Wiley Online Library under a Creative Commons license. With OnlineOpen, the author, the author's funding agency, or the author's institution pays a fee to ensure that the article is made open access. Authors of OnlineOpen articles are permitted to post the final, published PDF of their article on their personal website, and in an institutional repository or other free public server immediately after publication. All OnlineOpen articles are treated in the same way as any other article. They go through the journal's standard peer-review process and will be accepted or rejected based on their own merit.

OnlineOpen licenses. Authors choosing OnlineOpen retain copyright in their article and have a choice of publishing under the following Creative Commons License terms: Creative Commons Attribution License (CC BY); Creative Commons Attribution Non-Commercial License (CC BY NC); Creative Commons Attribution Non-Commercial-NoDerivs License (CC BY NC ND). To preview the terms and conditions of these open access agreements please visit the Copyright Terms and Conditions FAQs.

Funder Open Access and Self-Archiving Compliance: Please click here for more information on Wiley’s compliance with specific Funder Open Access and Self Archiving Policies, and click here for more detailed information specifically about self-archiving definitions and policies.


Editorial Office
Buddy Zhou
Managing Editor, CNS Neuroscience & Therapeutics
Tel: +86-21-80361204

Author Guidelines updated 29 May 2015